NEO

14.77

20.63% -3.84

Dopo l'orario di chiusura: 14.89 0.12 +0.81%

Neogenomics Inc (NEO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NEO Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$18.61

Aprire:

$17.75

Volume 24 ore:

2.55M

Relative Volume:

3.73

Capitalizzazione di mercato:

$1.90B

Reddito:

$628.25M

Utile/perdita netta:

$-78.55M

Rapporto P/E:

-23.82

EPS:

-0.62

Flusso di cassa netto:

$-29.73M

1 W Prestazione:

-13.02%

1M Prestazione:

-19.86%

6M Prestazione:

+9.25%

1 anno Prestazione:

-7.51%

Intervallo 1D:

$14.51

$17.75

Intervallo di 1 settimana:

$14.51

$19.11

Portata 52W:

$12.77

$19.11

Neogenomics Inc Stock (NEO) Company Profile

Nome

Neogenomics Inc

Settore

Healthcare (1232)

Industria

Diagnostics & Research (59)

Telefono

(239) 768-0600

Indirizzo

9490 NEOGENOMICS WAY, FORT MYERS, FL

Dipendente

2,100

Cinguettio

@NeoGenomics

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

NEO's Discussions on Twitter

Confronta NEO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NEO Neogenomics Inc	14.77	1.90B	628.25M	-78.55M	-29.73M	-0.62
TMO Thermo Fisher Scientific Inc	542.31	207.43B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	235.07	169.79B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	137.47	39.26B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	203.27	36.89B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	418.05	34.23B	3.84B	866.24M	792.60M	10.37

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-10	Iniziato	Jefferies	Buy
2024-05-01	Ripresa	Craig Hallum	Buy
2023-12-29	Reiterato	BTIG Research	Buy
2023-08-21	Aggiornamento	Stephens	Equal-Weight → Overweight
2023-05-16	Downgrade	Raymond James	Outperform → Mkt Perform
2023-05-09	Aggiornamento	BTIG Research	Neutral → Buy
2023-02-24	Aggiornamento	The Benchmark Company	Hold → Buy
2023-02-01	Aggiornamento	Needham	Hold → Buy
2022-08-26	Downgrade	The Benchmark Company	Buy → Hold
2022-08-22	Downgrade	Needham	Buy → Hold
2022-06-03	Iniziato	Piper Sandler	Overweight
2022-03-29	Downgrade	BofA Securities	Buy → Neutral
2022-03-29	Downgrade	Stephens	Overweight → Equal-Weight
2022-01-18	Ripresa	Stephens	Overweight
2021-12-16	Iniziato	Cowen	Outperform
2021-11-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-03	Iniziato	Goldman	Buy
2021-02-25	Ripresa	Needham	Buy
2021-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
2021-01-28	Iniziato	Truist	Buy
2020-12-11	Ripresa	BTIG Research	Buy
2020-10-28	Reiterato	Needham	Buy
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-08-28	Iniziato	Guggenheim	Buy
2020-07-29	Reiterato	Needham	Buy
2020-06-25	Iniziato	BofA/Merrill	Buy
2020-04-21	Ripresa	Stephens	Overweight
2020-03-02	Ripresa	Craig Hallum	Buy
2020-02-28	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Reiterato	Needham	Buy
2019-05-01	Reiterato	Needham	Buy
2019-03-29	Reiterato	Needham	Buy
2019-01-03	Iniziato	Needham	Buy
2018-10-24	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Iniziato	Leerink Partners	Outperform
2018-05-02	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Downgrade	BTIG Research	Buy → Neutral
2017-08-24	Iniziato	Gabelli & Co	Buy
2016-12-15	Iniziato	Cantor Fitzgerald	Overweight

Mostra tutto

Neogenomics Inc Borsa (NEO) Ultime notizie

01:55 AM

NeoGenomics CEO steps down, shares fall 17% By Investing.com - Investing.com Canada

11:38 AM

10:23 AM

NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance - MarketBeat

10:23 AM

09:23 AM

NeoGenomics (NEO) CEO Chris Smith to retire - StreetInsider.com

09:23 AM

08:34 AM

NeoGenomics, Inc. Reaffirms Earnings Guidance for Full Year Ended December 31, 2024 - Marketscreener.com

08:34 AM

07:57 AM

NeoGenomics Appoints Tony Zook As CEO - citybiz

07:57 AM

07:51 AM

NeoGenomics CEO Chris Smith to Retire; Tony Zook to Take Helm - MarketWatch

07:51 AM

07:34 AM

NeoGenomics Announces CEO Transition and Leadership Change - TipRanks

07:34 AM

07:06 AM

NeoGenomics Announces Chief Executive Officer Succession - The Bakersfield Californian

07:06 AM

07:05 AM

Neogenomics, Announces Retirement of Chris Smith as Board Member, Effective April 1, 2025 - Marketscreener.com

07:05 AM

Jan 09, 2025

Leerink Partnrs Weighs in on NeoGenomics FY2024 Earnings - MarketBeat

Jan 09, 2025

NeoGenomics (NASDAQ:NEO) Sets New 12-Month HighShould You Buy? - MarketBeat

Jan 09, 2025

Jan 08, 2025

NeoGenomics stock hits 52-week high at $19.01 amid growth By Investing.com - Investing.com South Africa

Jan 08, 2025

NeoGenomics stock hits 52-week high at $19.01 amid growth - Investing.com

Jan 08, 2025

Jan 06, 2025

NeoGenomics CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference - StockTitan

Jan 06, 2025

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian

Jan 06, 2025

Dec 31, 2024

NeoGenomics (NEO) Upgraded to Buy: Here's Why - MSN

Dec 31, 2024

Dec 29, 2024

The past three years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Simply Wall St

Dec 29, 2024

Dec 27, 2024

IBD Rating Upgrades: NeoGenomics Flashes Improved Price Strength - MSN

Dec 27, 2024

Dec 25, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 25, 2024

Dec 24, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Geode Capital Management LLC - MarketBeat

Dec 24, 2024

Dec 19, 2024

Franklin Resources Inc. Has $28.23 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Dec 19, 2024

Dec 18, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by State Street Corp - MarketBeat

Dec 18, 2024

Natera expands lawsuit against NeoGenomics over RaDaR test By Investing.com - Investing.com Canada

Dec 18, 2024

Dec 17, 2024

Natera expands lawsuit against NeoGenomics over RaDaR test - Investing.com India

Dec 17, 2024

Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics - Business Wire

Dec 17, 2024

Dec 15, 2024

Bank of America Raises NeoGenomics (NASDAQ:NEO) Price Target to $19.00 - Defense World

Dec 15, 2024

Dec 11, 2024

NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma - BioSpace

Dec 11, 2024

BNP Paribas Financial Markets Boosts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Dec 11, 2024

NeoGenomics' Breakthrough Study Shows Promise in Early Melanoma Detection Using RaDaR® Technology - StockTitan

Dec 11, 2024

Dec 10, 2024

Evaluating NeoGenomics: Insights From 4 Financial Analysts - Benzinga

Dec 10, 2024

NeoGenomics Getting Closer To Key Technical Measure - MSN

Dec 10, 2024

Dec 09, 2024

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting - Business Wire

Dec 09, 2024

Dec 08, 2024

Charles Schwab Investment Management Inc. Acquires 57,677 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Dec 08, 2024

Dec 07, 2024